An Update on the Long-Term Safety Experience of Ixekizumab: Results from the Psoriasis Clinical Development Program with More than 3 Years of Follow-up from 12 Clinical Trials and More Than 15000 Patient-Years of Exposure to Ixekizumab. J of Skin [Internet]. 2018 Dec. 17 [cited 2025 Apr. 14];2:S116. Available from: https://skin.dermsquared.com/skin/article/view/498